多疗程DC-CIK免疫疗法治疗晚期肺癌的临床疗效  

Clinical Efficacy of Multiple Courses of DC-CIK Immunotherapy in the Treatment of Advanced Lung Cancer

作　　者：周立莉 周冬霞 徐寿华 吴金芸 蔡茂怀 ZHOU Li-li;ZHOU Dong-xia;XU Shou-hua;WU Jin-yun;CAI Mao-huai(Department of Oncology,the Second People's Hospital of Yancheng,Yancheng 224000,Jiangsu,China;Bursley Biotechnology DevelopmentCo.Ltd.,Yancheng 224000,Jiangsu,China)

机构地区：[1]江苏省盐城市第二人民医院肿瘤内科,江苏盐城224000 [2]伯仕利生物科技发展<盐城>有限公司,江苏盐城224000

出　　处：《医学信息》2019年第20期5-8,共4页Journal of Medical Information

基　　金：盐城市医学科技发展计划项目(编号：YK2016019)

摘　　要：目的观察多疗程DC-CIK治疗晚期肺癌的临床疗效。方法选取2014年12月~2018年12月我院收治的化疗后肺癌患者86例,采用随机数字表法分为对照组和实验组,各43例。对照组行1个疗程DC-CIK治疗,实验组行3个疗程以上的DC-CIK治疗。比较两组治疗后疗效、淋巴细胞水平、细胞因子水平、肿瘤标志物表达以及不良反应发生情况。结果实验组疾病控制率(69.77%)高于对照组(41.86%)。治疗后两组CD4+、CD4+/CD8+、NK表达均较治疗前升高,且实验组高于对照组(P<0.05);治疗后两组CD8+表达均较治疗前下降,且实验组低于对照组(P<0.05);两组治疗前后IL-4、IL-6、IL-10无明显变化(P>0.05);治疗后两组IL-2、TNF-α、IFN-γ均较治疗前升高,且随着治疗次数增加,IL-2、TNF-α、IFN-γ逐渐升高(P<0.05);治疗后两组AFP、NSE、CYfra21-1均较治疗前下降(P<0.05);两组第一次治疗后CEA升高(P<0.05);实验组末次治疗后,CEA下降(P<0.05);两组均未出现不良反应。结论多疗程DC-CIK免疫疗法治疗晚期肺癌临床疗效确切,能有效清除肿瘤细胞,且安全无副作用。Objective To observe the clinical efficacy of multi-course DC-CIK in the treatment of advanced lung cancer.Methods 86 patients with lung cancer after chemotherapy from December 2014 to December 2018 were enrolled.The patients were divided into the control group and the experimental group by random number table,43 cases each.The control group received one course of DC-CIK treatment,and the experimental group received three courses of DC-CIK treatment.The therapeutic effects,lymphocyte levels,cytokine levels,tumor marker expression,and adverse reactions were compared between the two groups.Results The disease control rate(69.77%)in the experimental group was higher than that in the control group(41.86%).The expressions of CD4+,CD4+/CD8+and NK in the two groups were higher than those before treatment,and the experimental group was higher than the control group(P<0.05).The expression of CD8+in the two groups decreased after treatment,and the experimental group was lower than the control group(P<0.05).There was no significant change in IL-4,IL-6 and IL-10 before and after treatment(P>0.05).The latter two groups of IL-2,TNF-α,IFN-γwere higher than before treatment,and with the increase of treatment times,IL-2,TNF-α,IFN-γincreased gradually(P<0.05).After treatment,AFP,NSE and CYfra21-1 were lower than those before treatment(P<0.05);CEA increased after the first treatment in both groups(P<0.05);CEA decreased after the last treatment in the experimental group(P<0.05);no adverse reactions occurred in either group.Conclusion Multi-course DC-CIK immunotherapy is effective in the treatment of advanced lung cancer.It can effectively remove tumor cells and has no side effects.

关 键 词：DC-CIK 肺癌 免疫疗法 多疗程 

分 类 号：R734.2[医药卫生—肿瘤]